Marcus Vale
Performance Writer
Men 35–50 optimizing energy, body composition and testosterone
Marcus Vale covers performance and metabolic health for men in the thick of midlife — testosterone, training, stress and turning the dad-bod years into the strongest decade yet. Practical, skeptical of fads, and allergic to bro-science.
Latest articles
Ozempic on the OR Table: The New Pre-Surgery Fasting Playbook for GLP-1 Users
A 2026 systematic review reframes the pre-anesthesia question for semaglutide users — less about pausing the drug, more about clearing the stomach and checking it with ultrasound.
Beyond Weight Loss: Tirzepatide's Inflammation Signal and the Combo Therapy Shift
New meta-analyses suggest the metabolic-drug story is moving past the scale — toward measurable inflammation reduction and stacked cardiorenal protection. Here's what that actually changes for a 40-year-old.
GLP-1s Beyond Weight: Bladder Benefits, Bowel Risks, and the Post-Bariatric Rescue
Semaglutide's clinical footprint is widening fast — new data hint at off-target wins, real-world rescues, and a sharpening list of who should pause before the pen.
The CTI Score: A Sharper Lens on Cardiovascular-Kidney-Metabolic Risk
A new composite index built from C-reactive protein, triglycerides and glucose tracked 7,280 adults for nearly a decade — and outperformed its parts at flagging who progressed.
GLP-1 Under the Microscope: What Liraglutide's Self-Assembly Reveals About the Next Wave of Weight-Loss Drugs
A new flow-NMR study cracks open how a marketed GLP-1 drug quietly rearranges itself in solution — and why that matters for the next generation of injectables busy men will actually use.
GLP-1s Keep Surprising Us: New Signals on Asthma, the Heart, and a Strange Ear Problem
The same drugs reshaping body composition are now generating clinical surprises in both directions — including a side effect nobody saw coming.
Drive-Thru Gut: New Evidence Links Daily Fast Food to IBD Risk
A Riyadh case-control study paired with a fresh meta-analysis sharpens the dietary case against fast food in inflammatory bowel disease — and gives busy men a concrete lever to pull.
The New Peptide Pipeline: How AI Is Quietly Rewiring Drug Discovery
Computational design is pushing peptide therapeutics into oncology, infectious disease, and antimicrobial resistance. The early signals are real — and the caveats matter.
GLP-1s Go Cardio: What a New Meta-Analysis Says About Heart Attack Risk
A 109,000-patient meta-analysis sharpens the case that GLP-1 receptor agonists are cardiometabolic drugs, not just weight-loss tools — with concrete numbers on who actually benefits.
Cardiometabolic Resilience: Who Avoids the Damage, and Why It Matters for You
Two new datasets reframe metabolic risk from inevitability to variability — hunting the protective phenotypes that shrug off vascular damage, and the routine labs that flag your five-year diabetes window.
GLP-1s Go Under the Knife: What New Surgical Data Mean for Ozempic-Class Users
Fresh cohort analyses say the perioperative picture is procedure-specific — reassuring at the hip, worrying at the shoulder — and shortages keep complicating the calculus.
Semaglutide's Cardiovascular Dividend: What the Latest Meta-Analyses Reveal
Two fresh syntheses sharpen the picture of how the most-talked-about GLP-1 protects the heart — and where the evidence still has gaps.